Tempest Therapeutics, Inc. Appoints Andrew Fang As Head Of Business Development To Drive Global Partnerships And China Expansion

Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing advanced CAR-T cell therapy product candidates for cancer, announced the appointment of Andrew Fang, Ph.D., as its new Head of Business Development. In this role, Dr. Fang will oversee all global business development initiatives, including strategic partnerships, cross-border licensing, and corporate transactions. A key focus of his work will be expanding Tempest’s partnering activities and outreach efforts in China, a major strategic region for the company.

The decision to appoint Dr. Fang reflects Tempest’s increased emphasis on making business development a central part of its long-term strategy. This includes pursuing potential partners for amezalpat, the company’s Phase 3-ready small-molecule program, while also strengthening strategic collaborations across Tempest’s expanding CAR-T portfolio.

Dr. Matt Angel, President and Chief Executive Officer of Tempest, stated that the company is pleased to welcome Dr. Fang to the leadership team. He noted that Dr. Fang brings extensive experience in cross-border licensing, strategic transactions, and capital markets, especially within the U.S. and Chinese biotechnology sectors. As Tempest actively seeks a partner for its Phase 3-ready amezalpat program and moves forward with development opportunities in China following regulatory clearance for a pivotal trial, Dr. Angel emphasized that Dr. Fang’s background and network will be valuable assets.

Tempest is continuing to prioritize strategic partnerships for amezalpat, which is being developed for the treatment of hepatocellular carcinoma (HCC). The company recently received clearance to begin a pivotal study of amezalpat in China, building on prior alignment with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the Phase 3 study design. These regulatory accomplishments position amezalpat for potential global development and open new opportunities for regional partnerships and cross-border collaborations.

Dr. Fang joins Tempest with a strong track record in biotechnology strategy and deal-making. He is a Founding Partner and Principal at YQ Advisors, where he focuses on strategic transactions, value creation, and emerging technology platforms. His experience spans cross-border licensing, asset-level transactions, biotech financing, and initiatives involving publicly listed biotechnology companies.

Expressing his enthusiasm for the new role, Dr. Fang said he is excited to join Tempest at a pivotal moment in its growth. He highlighted the strength of the company’s portfolio, which includes a Phase 3-ready asset supported by regulatory clearance and a growing CAR-T platform aimed at addressing unmet needs in oncology. He noted that he looks forward to helping Tempest advance its business development strategy and pursue partnerships that can generate value for both patients and shareholders.

At YQ Advisors, Dr. Fang has been involved in ex-China and global licensing, M&A transactions, and reverse-merger opportunities within the biotech sector. He has also played key roles in incubating early-stage biotechnology platforms, particularly in the areas of cell and gene therapy and AI-driven biotechnology. With deep experience in CAR-T and strong connections across Chinese biotech clinical resources, strategic investors, and operational partners, Dr. Fang brings expertise that will support the evaluation, development, and positioning of Tempest’s innovative therapeutic programs.